News

A phase III trial evaluating the efficacy of nivolumab (Opdivo) for the treatment of advanced renal cell carcinoma has been stopped early after the immunotherapy agent demonstrated a survival advantage over the comparator drug, everolimus (Afinitor), in the CheckMate-025 trial.

This summer the Cancer Support Community is hosting four "Frankly Speaking About Cancer" webinars on a variety of different topics to help your patients live well with cancer.